Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature

Analytical Cellular Pathology

Volumn 23, Issue 3-4, 2001, Pages 107-128

  Davidson, Ben ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CA 125 ANTIGEN; CARBOHYDRATE ANTIGEN; COLONY STIMULATING FACTOR 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DESMIN; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; FIBRONECTIN; GLUTATHIONE TRANSFERASE; GROWTH FACTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6; LECTIN; MATRIX METALLOPROTEINASE; MULTIDRUG RESISTANCE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLATINUM DERIVATIVE; PROTEIN P21; PROTEIN P53; SELECTIN; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE; UVOMORULIN; VASCULOTROPIN;

ARTICLE; CANCER DIAGNOSIS; CYTOPATHOLOGY; EPITHELIUM CELL; GENOTYPE; HUMAN; MESOTHELIUM CELL; METASTASIS; MULTIMODALITY CANCER THERAPY; OVARY CARCINOMA; PERITONEUM; PHENOTYPE; PLEURA EFFUSION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 0035740826     PISSN: 09218912     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/418547     Document Type: Article

References (236)

1. Global cancer statistics
2. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
3. Ovarian neoplasms
4. Therapy and prognosis of ovarian carcinoma
5. Surface epithelial-stromal tumors
6. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer
7. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer - A multivariate analysis
8. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and literature review
9. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer
10. Effect of surgical debulking on survival in stage IV ovarian cancer
11. Current status of chemotherapy in gynecologic cancer
12. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
13. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
14. Stage IV ovarian cancer: Impact of surgical debulking
15. FIGO stage histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva and vagina
16. Epithelial carcinoma of the ovary in the reproductive years. Clinical and morphological characterization
17. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience
18. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary
19. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma
20. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
21. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study
22. Combined morphologic and cytochemical grading of serous ovarian tumors
23. DNA flow cytometry of ovarian tumors with correlation to histopathology
24. Clinicopathologic variables, operative characteristics and DNA ploidy in predicting outcome in ovarian epithelial carcinoma
25. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis
26. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
27. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
28. Overexpression of the oncogene c-erbB2 in primary ovarian cancer. Evaluation of the prognostic value in a Cox proportional hazards multiple regression
29. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
30. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
31. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer, I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer
32. Significance of epidermal growth factor receptor in advanced ovarian cancer
33. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: A pilot study
34. Epidermal growth factor expression has no independent prognostic significance in advanced ovarian cancer
35. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
36. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade and stage
37. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis
38. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer
39. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival
40. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: A poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1
41. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
42. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients
43. The significance of urokinase-type plasminogen activator, its inhibitor and its receptor in ascites of patients with epithelial ovarian cancer
44. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF-1
45. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
46. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer
47. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy
48. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
49. Vascular endothelial growth factor serum concentrations in ovarian cancer
50. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystadenocarcinomas: Relationship with MIB1 immunostaining
51. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival and analysis of serum VEGF levels
52. Vascular endothelial growth factor expression in early-stage ovarian carcinomas
53. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
54. The expression of vascular endothelial growth factor and transforming growth factor-β associates with angiogenesis in epithelial ovarian cancer
55. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas
56. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma
57. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
58. nm23 in ovarian cancer: Correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters
59. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: Correlation with tumour progression and nm23 gene expression
60. Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: Association with high messenger RNA expression with lack of lymph node metastasis
61. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: Correlation with clinicopathology, EGFR, c-erbB-2 and c-erb-B3 genes, and sex steroid receptor expression
62. Prognostic significance of ras/p21 alterations in human ovarian cancer
63. Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome
64. Expression of cadherins in benign, borderline and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases
65. Clinical significance of α-catenin, collagen IV and Ki-67 expression in epithelial ovarian cancer
66. β-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with β-catenin gene mutations, clinicopathological features and clinical outcome
67. Mucin gene expression in ovarian cancers
68. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer
69. Symptomatology of ovarian cancer
70. Ovarian cancer stages I and II: Predictions and 5-year survival in two decades
71. Pathogenesis of ascites in peritoneal carcinomatosis
72. The genesis of ascites in ovarian cancer
73. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma
74. Prognostic factors in patients with stage I epithelial ovarian cancer
75. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma
76. Correlation of ascitic fluid cytology with histologic findings before and after treatment of ovarian cancer
77. The prognostic significance of residual disease, FIGO substage, Tumor histology and grade in patients with FIGO stage III ovarian cancer
78. The prognostic implication of ascites in advanced-stage ovarian cancer
79. Survival determinants in patients with advanced ovarian cancer
80. Survival of women with advanced ovarian cancer and complete pathologic response at second look laparotomy
81. Characterization and survival of patients with serous cystadenocarcinoma of the ovaries
82. Prognostic factors in extraovarian primary peritoneal carcinoma
83. Suppression of E-cadherin and alpha- and beta-catenin mRNA expression in the metastatic lesions of gynecological cancers
84. Expression of E-cadherin and alpha- and beta-catenin mRNA in ovarian cancers
85. Expression of E-cadherin in normal, benign and malignant tissues of female genital organs
86. E-cadherin expression in human epithelial ovarian cancer and normal ovary
87. A defect in cell-to-cell adhesion via integrin-fibronectin interactions in a highly metastatic tumor cell line
88. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models
89. Expression of cell adhesion molecules on ovarian tumor cell lines and mesothelial cells, in relation to ovarian cancer metastasis
90. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin
91. Novel sulfated ligands for the cell adhesion molecule E-selectin revealed by the neoglycolipid technology among o-linked oligosaccharides on an ovarian cystadenoma glycoprotein
92. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule (VCAM-1) in human malignancies
93. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin
94. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms
95. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers
96. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer
97. Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer
98. Collagenase expression in ovarian cancer cell lines
99. Altered expression of basement-membrane components and collagenases in ascitic xenographs of OVCAR-3 ovarian cancer cells
100. MMP-2 release and activation in ovarian carcinoma: The role of fibroblasts
101. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies
102. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues
103. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors. Possible implications for the role of desmoplastic fibroblasts
104. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines
105. 72-KiloDalton type IV collagenase, type IV collagen and Ki 67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical and serological study
106. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications
107. Expression and activity of MMPS and their regulators in ovarian cancer
108. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary
109. Expression of 72 kilo-dalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors
110. Diagnostic problems in serous effusions
111. Cytologic findings in peritoneal washings associated with benign geyecologic disease
112. Cytohistologic correlation of peritoneal washing cytology in gynecologic disease
113. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms
114. Peritoneal washings in ovarian tumors. Potential sources of error in cytologic diagnosis
115. Cytology of peritoneal washings in gynecologic patients. Diagnostic criteria and pitfalls
116. Müllerian inclusions in washings. Potential source of error in cytologic diagnosis
117. Endosalpingiosis in female peritoneal washings: A diagnostic pitfall
118. Florid mesothelial hyperplasia associated with ovarian tumors: A potential source of error in tumor diagnosis and staging
119. "Thick" cell membranes revealed by immunohistochemical staining: A clue to the diagnosis of mesothelioma
120. Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis
121. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry
122. Markers for metastatic adenocarcinoma in serous effusion specimens
123. Immunohistochemistry in the differential diagnosis of effusions: Use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations
124. Immunocytochemical panel for the identification of malignant cells in serous effusions
125. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis and reactive mesothelium in serous effusions
126. Quality control of immunocytochemical staining of effusions using a standardized method of cell processing
127. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin
128. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions
129. Comparison of monoclonal antibodies AUA1 and BER EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells
130. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1
131. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serous effusions
132. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies
133. Atypical cells in effusions: Diagnostic value of cell image analysis combined with immunocytochemistry
134. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
135. Utility of Ber-EP4 in the diagnosis of adenocarcinoma in effusions: An immunocytochemical study of 232 cases
136. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells
137. E-cadherin, N-Cadherin and calretinin in pleural effusions: The good, the bad, the worthless
138. The cell adhesion molecule, E-Cadherin, distinguishes mesothelial cells from carcinoma cells in fluids
139. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma and adencarcinoma: Utility of combined E-cadherin and calretinin immunostaining
140. Utility of the antibodies CA 19-9, HMBE-1 and Thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology
141. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions
142. Desmin expression in reactive mesothelium: A potential aid in evaluation of gynecologic specimens
143. Lectin binding properties of cells from serous effusion and peritoneal washing specimens
144. Distinguishing benign from malignant pleural effusions by lectin immunocytochemistry
145. Diagnostic value of p53 protein and flow cytometric DNA analysis in the study of serous effusions
146. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant effusions
147. Multiparameter flow cytometric DNA analysis of effusions: A prospective study of 36 cases compared with routine cytology and immunohistochemistry
148. Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma
149. Diagnostic value of DNA analysis in effusions by flow cytometry and image analysis
150. Static DNA cytometry as a diagnostic aid in effusion cytology. I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes
151. Static DNA cytometry as a diagnostic aid in effusion cytology. II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions
152. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
153. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: Basic considerations and recommendations for preparation, measurement and interpretation
154. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations for quality assurance
155. Expression of carcinoembryonic antigen in fresh human gastric cancer cells assessed by flow cytometry
156. Aneuploidy of chrosome 8 as detected by interphase fluoroscence in situ hybridization is a recurrent finding in primary and metastatic breast cancer
157. Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interface cytogenetics: Basic findings and clinical aspects
158. Interface fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients
159. Cytogenetic and cell cycle studies in metastatic cells from ovarian carcinomas
160. Cytogenetic study of cancer cells in effusions
161. Double minutes in prematurely condensed chromatin of human tumor cells
162. Incidence of double minutes, cytogenetic equivalents of gene amplifications, in human carcinoma cells
163. Detection of chromosomal aberrations in tumor cells and tumor infiltrating lymphocytes by molecular cytogenetics in patients with gynecological cancer
164. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
165. Detection of hyperdiploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization
166. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology
167. Chromosome aberrations in nine patients with ovarian cancer
168. DNA ploidy S-phase and Ki-67 antigen expression in the evaluation of cell content of pleural effusions
169. p53 and PCNA coexpression of 81 pleural and peritoneal specimens: An immunohistochemical study
170. Comparison of nucleolar organizer regions and DNA flow cytometry in the evaluation of pleural effusion
171. Distribution of silver-stained interphase nucleolar organizer regions as a parameter to distinguish neoplastic from non-neoplastic reactive cells in human effusions
172. Morphometric analysis of nucleolar organizer regions in benign and malignant peritoneal washings using backscattred electron microscopy
173. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions
174. Relationships between Fas expression, activation molecule CD25 and functional activity of tumor-associated lymphomonocytes from neoplastic effusions
175. Diagnostic value of p53 protein in the study of serous effusions
176. Expression of p21waf1/cip1, MDM2 and p53 in vivo: Analysis of cytological preparations
177. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens
178. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology
179. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells
180. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells
181. Tumor oncogenic expression in malignant effusions as a possible method to enance cytologic diagnostic sensitivity. An immunohist ochemical study of 87 cases
182. C-myc expression in exfoliated cells in serous effusions
183. C-erbB-2 oncoprotein immnustaining in serous effusions
184. Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination
185. Detection of c-Ha-ras oncogene expression in pleural and peritoneal smear effusion by in situ hybridization
186. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer
187. Molecular lesions involved in the progression of a human breast cancer
188. Differential expression of CD44 splice variants in malignant and benign pleural effusions
189. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies
190. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material
191. Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid
192. Pleural mesothelioma mimics the integrin profile of activated, sessile, rather than detached mesothelial cells
193. CEA-mediated homotypic aggregation of human colorectal cells in malignant cells in a malignant effusion
194. Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions
195. Expression of intercellular adhesion molecule-1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma
196. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3 and CA 19-9 assay in pleural fluid. A study of 207 patients
197. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer
198. Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer
199. A Latent form of cathepsin B in pleural effusions. I. Characterization of the enzyme in breast cancer patients
200. MMP and Timp expression pattern in pleural effusions of different origins
201. Human pleural effusions are rich in matrix metalloproteinases
202. Transforming growth factor-alpha activity in effusions: Comparison of radioimmunoassay and radioreceptorassay
203. Expression of platelet-derived growth factor (PDGF) receptors in human malignant mesothelioma in vitro and in vivo
204. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions
205. Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions
206. Markedly elevated levels of vascular endothelial factor in malignant ascites
207. Vascular endothelial growth factor in the sera and effusions of patients with malignant and non-malignant ascites
208. Telomerase activity in pleural effusions: Diagnostic significance
209. Detection of telomerase expression in fine-needle aspirations and fluids
210. Telomerase activity in human gynecological malignancies
211. Telomerase activity in benign and malignant cytologic fluids
212. Cytological diagnosis and telomerase activity of cells in effusions of body cavities
213. Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: A comparative study of three monoclonal antibodies, JSB-1, C219 and 265/F4, against different epitopes using frozen and paraffin tissue sections
214. Peritoneal washing cytology in gynecologic cancers: Long-term follow-up of 355 patients
215. The prognostic value of peritoneal cytology in gynecologic malignant disease
216. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies - Evaluation of five epithelial markers
217. Carbohydrate antigen expression in primary tumors, metastatic lesions and serous effusions from patients diagnosed with epithelial ovarian carcinoma - Evidence of up regulated Tn and Sialyl Tn antigens expression in effusions
218. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases - A clinicopathologic study
219. E-cadherin and α-, β- and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
220. E-cadherin complex protein expression and survival in ovarian carcinoma
221. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
222. Expression of membrane-type 1,2 and 3 matrix metalloproteinases (MT1-MMP, MT2-MMP, MT3-MMP) mRNA in ovarian carcinoma cells in serous effusions
223. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
224. ECM cellsurface proteolysis: Regulating cellular ecology
225. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression
226. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohisto-chemistry and mRNA in situ hybridization
227. Mutations of the E-cadherin gene in human gynecologic cancers
228. α-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with -catenin gene mutations, clinicopathological features and clinical outcome
229. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma
230. αV integrin is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
231. Up-regulation of CD44s, but not of CD44v3-10, in ovarian carcinoma cells in malignant effusions
232. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions
233. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients